Results 181 to 190 of about 25,303 (250)

Inhibition of proprotein convertase SKI-1 prevents blood vessel alteration after stroke. [PDF]

Nat Cardiovasc Res
Shabanzadeh AP, Ringuette D, Syonov M, Wu Q, Tassew NG, Mun EK, Meek A, Lively S, Suntharalingham SE, Mojica M, Olijnyk L, Qiang B, Foltz WD, Reed M, Moya I, Brown C, Feng J, Qin X, Akula PS, Wälchli T, Carlen PL, Alcaide-Leon P, Monnier PP.   +22 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury. [PDF]

Kidney Med
Strimaitis BJ, Francis L, O'Sullivan ED.
europepmc   +1 more source

Alterations in the Expression of Proprotein Convertase Genes in Human Esophagus Squamous Cell Carcinomas. [PDF]

Acta Naturae
Komissarov AA, Zinovyeva MV, Sass AV, Vinogradova TV, Koshechkin SI, Demkin VV, Zborovskaya IB, Kostrov SV, Demidyuk IV.   +8 more
europepmc   +1 more source

Association between proprotein convertase subtilisin/kexin type 9 targeted therapies and the risk of arrhythmias: a meta-analysis of randomized controlled trials. [PDF]

Am J Prev Cardiol
Jaiswal V, Goyal A, Deb N, Shama N, Mittal V, Rajak K, Halder A, Khadka S, Kumar T, Ahmed R, Bytyçi I, Banach M, Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group.   +12 more
europepmc   +1 more source

Correction: Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review. [PDF]

Cureus
Rabih AM, Niaj A, Raman A, Uprety M, Calero MJ, Villanueva MRB, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Mohammed L.   +12 more
europepmc   +1 more source

Pathogenic Deep Intronic PCSK1 Variant Causes Proprotein Convertase 1/3 Deficiency in a Family. [PDF]

Clin Genet
Huber LM, Subaşıoğlu A, Garczarczyk-Asim D, Valovka T, Müller T, Adam R, Janecke AR.   +6 more
europepmc   +1 more source

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients. [PDF]

Cureus
Patra V, Yella VR, Konda VGR, Sayana SB, Siripuram C, Konka S, Kandimalla R.   +6 more
europepmc   +1 more source

Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]

PeerJ
Li Z, Li X, Zhang Y, Qi J, Ji L, Li S, Gu M, Liu Y, Zhang Y, Mei Y, Wang M, Zhou J, Su M, Zhu L, Deng Q.   +14 more
europepmc   +1 more source

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach. [PDF]

Eur J Med Res
Zheng X, Yuan W, Li L, Ma H, Zhu M, Li X, Feng X.   +6 more
europepmc   +1 more source

Dysregulation of FURIN and Other Proprotein Convertase Genes in the Progression from HPV Infection to Cancer. [PDF]

Int J Mol Sci
Izaguirre G, Zirou N, Meyers C.
europepmc   +1 more source